Teva Agilect “Approvable” For Parkinson’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is pursuing an indication for rasagiline as monotherapy in early Parkinson’s disease and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease.
You may also be interested in...
FDA Extends Agilect User Fee Deadline Due To “Technical Error”
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.
FDA Extends Agilect User Fee Deadline Due To “Technical Error”
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.
Agilect Could Launch In Mid-2005 After Teva Responds To “Approvable” Letter
Written response will trigger FDA’s six-month review clock, setting an estimated action date in May. Teva and Eisai plan to launch the Parkinson’s disease therapy within two months following approval.